Multiple System Atrophy - Global Strategic Business Report

The global market for Multiple System Atrophy was valued at US$145.2 Million in 2025 and is projected to reach US$173.2 Million by 2032, growing at a CAGR of 2.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Multiple System Atrophy Market - Key Trends & Drivers Summarized

Why Is Multiple System Atrophy a Focus Area in Neurodegenerative Disease Research?

Multiple System Atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects multiple regions of the central nervous system, leading to a combination of movement, autonomic, and cerebellar symptoms. The disease shares features with Parkinson’s disease but progresses more rapidly and lacks sustained response to dopaminergic therapy. Diagnosis is clinically challenging due to symptom overlap with other movement disorders, often resulting in delayed intervention. This complexity has placed MSA under increased clinical and research attention, particularly as early and accurate diagnosis is critical for care planning and trial enrollment.

The condition is categorized into two subtypes: MSA-P (parkinsonian) and MSA-C (cerebellar), depending on the predominant symptom profile. Both forms involve widespread alpha-synuclein accumulation in glial cells, distinguishing MSA pathologically from Parkinson’s and other related disorders. Management is currently symptomatic, focusing on improving quality of life through pharmacological and supportive therapies, as no curative treatment exists. This unmet need continues to drive new approaches in diagnostics, disease-modifying therapies, and multidisciplinary care frameworks.

What Therapeutic Strategies Are Being Explored to Address MSA?

Current treatment strategies remain palliative, aimed at managing motor symptoms with dopaminergic agents and addressing autonomic dysfunction with medications that stabilize blood pressure, bladder function, and sleep disturbances. However, limited and short-lived responses highlight the urgent need for disease-modifying options. Several research programs are now investigating approaches that target alpha-synuclein aggregation, neuroinflammation, and mitochondrial dysfunction, which are believed to underlie disease progression.

Clinical trials are evaluating small molecules, monoclonal antibodies, and gene therapies that intervene in neurodegenerative pathways. Some investigational drugs aim to slow glial cell damage or modulate immune system activity within the brain. Interest is also growing in regenerative strategies, including stem cell-based therapies, though these remain at early research stages. As research continues, patient registries, biomarker identification, and improved imaging tools are playing a key role in refining study designs and enabling earlier intervention.

Which Healthcare Systems and Patient Needs Influence Market Dynamics?

Due to its rarity, MSA is typically managed at specialized neurology centers that offer coordinated care from movement disorder specialists, autonomic experts, and rehabilitative professionals. The condition places a high burden on caregivers and healthcare systems due to its rapid progression and multi-system involvement. Patients often require a combination of pharmacological support, physical therapy, speech therapy, and assistive technologies. Early access to multidisciplinary care and patient education can delay complications and improve day-to-day functioning.

Public awareness remains low, leading to underdiagnosis and inconsistent care pathways across different regions. Advocacy organizations are working to expand education, patient support, and clinical trial participation. Diagnostic uncertainty continues to hinder access to targeted treatments and appropriate referrals. Increasing awareness among primary care physicians and neurologists is essential to improve early detection and reduce misdiagnosis rates, which currently remain high for MSA.

Growth in the Multiple System Atrophy Market Is Driven by Several Factors

Growth in the multiple system atrophy market is driven by several factors. Rising diagnostic capabilities and neuroimaging tools are improving identification and subtyping of patients. Increased research investment in rare neurodegenerative diseases is leading to more clinical trials targeting underlying disease mechanisms. Expansion of patient advocacy networks supports awareness, education, and trial recruitment. Advances in biomarker research and imaging methods facilitate earlier diagnosis and intervention. Broader access to multidisciplinary care models and symptom management strategies improves long-term patient outcomes. Lastly, regulatory interest in supporting orphan drug development accelerates innovation and investment in this challenging and underserved disease area.

Report Scope

The report analyzes the Multiple System Atrophy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Diagnosis Type (Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test, Other Diagnosis Types); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Magnetic Resonance Imaging segment, which is expected to reach US$71.8 Million by 2032 with a CAGR of a 3.3%. The Positron Emission Tomography segment is also set to grow at 1.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $39.6 Million in 2025, and China, forecasted to grow at an impressive 4.6% CAGR to reach $33.5 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Multiple System Atrophy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Multiple System Atrophy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Multiple System Atrophy Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AC Immune, Alterity Therapeutics, Asklepios BioPharmaceutical (AskBio), AstraZeneca plc, Biohaven Pharmaceuticals and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Multiple System Atrophy market report include:

• AC Immune
• Alterity Therapeutics
• Asklepios BioPharmaceutical (AskBio)
• AstraZeneca plc
• Biohaven Pharmaceuticals
• Biogen Idec
• Brain Neurotherapy Bio, Inc.
• Corestem, Inc.
• H. Lundbeck A/S
• Inhibikase Therapeutics
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Modag GmbH
• Neuramedy
• ProMIS Neurosciences Inc.
• Retrotpe
• Sanofi S.A.
• Stealth BioTherapeutics Corp.
• Theravance Biopharma, Inc.
• Teva Pharmaceutical Industries Ltd.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.